Compositions and methods for analysis, detection, and treatment of multiple sclerosis
AssigneeThe Regents of the University of Michigan
InventorsQi Wu, Yang Mao-Draayer
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to materials and methods for prognostic classification of multiple sclerosis patients. In particular, provided herein are biomarkers and methods of uses thereof for stratifying patients with multiple sclerosis. The methods described herein facilitate selection of an appropriate treatment for a subject.
Claims13
-52. (canceled)
A method comprising measuring protein expression levels of at least 6 proteins in a sample obtained from a subject having or suspected of having multiple sclerosis, wherein the at least 6 proteins are selected from soluble CD40L (sCD40L), Monocyte Chemoattractant Protein-1 (MCP-1), gamma interferon (IFNγ) epidermal growth factor (EGF), neurofilament light chain (NFL), fractalkine/CX3CL1, interleukin-13 (IL-13), Eotaxin, lymphotoxin-alpha (TNFβ/LTα), and interleukin-12 subunit p40 (IL-12p40).
Dependencies are inferred from the claim text.